support: from: Amgen, BMS, Janssen, Roche, UCB, AbbVie, Pfizer, Merck, Celgene, Sanofi, Lilly, Novartis., Carol Hinton Grant/research support from: Pfizer and UCB Canada, Glen Hazlewood: None declared, Edward Keystone Speakers bureau: UCB, Pfizer, Abbvie, Lilly, Ph鄂ebe, Bristol-Myers Squibb, F. Hoffmann-La Roche Inc, Janssen Inc., Merck, Pfizer Pharmaceuticals, Sanofi Genzyme, UCB, Consultant of: AbbVie, Amgen, AstraZeneca Pharma, Bristol-Myers Squibb Company, Celltrion, Myriad Autoimmune, F. Hoffmann-La Roche Inc, Genentech Inc, Gilead, Janssen Inc, Lilly Pharmaceuticals Merck, Pfizer Pharmaceuticals, Sandoz, Sanofi Genzyme, Samsung Bioepis, Grant/research support from: AbbVie, Amgen, Gilead Sciences Inc, Lilly Pharmaceuticals, Pfizer Pharmaceuticals, Puratharm, Sanofi, Ont Schehr: None declared, Carter Thorne Speakers bureau: Medexus, Medac, Consultant of: Abbv, Centocor, Janssen, Lilly, Medecux,Medac, Pfizer, Grant/research support from: Amgen, Pfizer, Abbvie, Celgene, CareBiodam, Novartis, Diane Tin: None declared, Marie-France Valois: None declared, Vivian Bykerk Consultant of: Amgen, BMS, Gilead, Sanofi-Genzyme/Regeneron, Pfizer Pharmaceuticals, UCB, NIH, Lillian Barra: None declared

Bykerk Consultant of: Amgen, BMS, Celgene, CareBiodam, Novartis, Diane Tin: None declared, Marie-France Valois: None declared, Vivian Bykerk Consultant of: Amgen, BMS, Gilead, Sanofi-Genzyme/Regeneron, Pfizer Pharmaceuticals, UCB, NIH, Lillian Barra: None declared

Conclusion: In RA patients treated with PSL, average PSL dose of only 1mg/day significantly increased the risk for the incidence of clinical fractures. Even for established RA patients, continuous use or initiation of low PSL dose was apparently significant risk factor for clinical fractures.

Disclosure of Interests: Hitoshi Yoshimura: None declared, Tatsuya Koike Grant/research support from: Takeda Pharmaceutical, Mitsubishi Tanabe Pharma Corporation, Chugai Pharmaceutical, Eisai, Abbott Japan, Teijin Pharma, Banyu Pharmaceutical and Ono Pharmaceutical, Kenji Mamoto: None declared, Yuko Sugio: None declared, Tadasahi Okano: None declared, Masahiro Tada: None declared, Kentaro Inui Grant/research support from: Janssen Pharmaceutical, K.K. and Astellas Pharma Inc, Hiroaki Nakamura: None declared

DOI: 10.1136/annrheumdis-2021-eular.1886

Table 1. LDL cholesterol serum levels and LDL goals differences between baseline and final follow-up

<table>
<thead>
<tr>
<th>LDL (mg/dl) ESC 2016 goals</th>
<th>n</th>
<th>% Baseline</th>
<th>Final</th>
<th>Goal</th>
<th>Baseline</th>
<th>Final</th>
<th>p follow-up</th>
</tr>
</thead>
<tbody>
<tr>
<td>Low</td>
<td>120</td>
<td>37</td>
<td>116</td>
<td>37</td>
<td>0.081</td>
<td>&lt; 130</td>
<td>68%</td>
</tr>
<tr>
<td>Moderate</td>
<td>195</td>
<td>62</td>
<td>133</td>
<td>29</td>
<td>0.000</td>
<td>&lt; 115</td>
<td>35%</td>
</tr>
<tr>
<td>High</td>
<td>7</td>
<td>2</td>
<td>121</td>
<td>26</td>
<td>0.14</td>
<td>&lt; 100</td>
<td>14%</td>
</tr>
<tr>
<td>Very High</td>
<td>5</td>
<td>0</td>
<td>131</td>
<td>41</td>
<td>0.080</td>
<td>&lt; 70</td>
<td>0%</td>
</tr>
</tbody>
</table>

ESC: European Society of Cardiology; EULAR: European League Against Rheumatism. SCORE: Systematic COronary Risk Evaluation; RA: Rheumatoid Arthritis; LDL: low-density lipoprotein. Significant p value are depicted in bold.

When patients with RA, regardless the SCORE risk they had, were divided between those that attained LDL-cholesterol target or not, those that achieved their LDL goal, were more frequently female and had less diabetes mellitus. Moreover, a higher level of achieving LDL-cholesterol goal was higher in those with an inferior total cholesterol, LDL-c and atherogenic index at baseline, independently, no differences were observed in both populations regarding the baseline use of statins, aspirin or hypertension treatment at baseline. Concerning disease related data when study started, no differences about disease duration and activity or treatments were observed between dose that reached LDL-cholesterol goal and those that did not.

Those that achieved LDL-c objectives had a higher decrease in smoking quit and a superior control of hypertension. Besides, in those that attained objectives a